Life extension requires careful consideration of resource scarcity, justice, and what, if anything, is intrinsic to the experiences we define as human.
AMA J Ethics. 2019;21(5):E470-474. doi:
10.1001/amajethics.2019.470.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Medical students’ moral distress about end-of-life cases can be reduced through ethics consultation and ethics rounds, narrative reflection, and mentoring.
AMA J Ethics. 2017;19(6):585-594. doi:
10.1001/journalofethics.2017.19.6.stas1-1706.
The convening power of clinical ethics committees stems from their reputation for fairness and procedural legitimacy in addressing and resolving ethically complex cases.
AMA J Ethics. 2016;18(5):540-545. doi:
10.1001/journalofethics.2016.18.5.msoc2-1605.